MariMed SG&A Expenses 2012-2024 | MRMD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

MariMed sg&a expenses from 2012 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

MariMed sg&a expenses from 2012 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.

Related Stocks
Company Name	Market Cap
Abbott Laboratories (ABT)	$222.4B
Boston Scientific (BSX)	$154.8B
Stryker (SYK)	$151B
EssilorLuxottica (ESLOY)	$128.8B
Medtronic (MDT)	$116.5B
Lonza Group Ag (LZAGY)	$48.7B
Haleon (HLN)	$43B
Agilent Technologies (A)	$42.1B
GE HealthCare Technologies (GEHC)	$40.5B
ResMed (RMD)	$34.8B
Terumo (TRUMY)	$27.7B
Koninklijke Philips (PHG)	$25.8B
Zimmer Biomet Holdings (ZBH)	$20.4B
Insulet (PODD)	$20.2B
Baxter (BAX)	$15.7B
Smith & Nephew SNATS (SNN)	$11B
Sunny Optical Technology (SNPTF)	$10B
BellRing Brands (BRBR)	$10B
Bio-Rad Laboratories (BIO)	$9.7B
Demant (WILYY)	$7.9B
Lantheus Holdings (LNTH)	$6.3B
Prestige Consumer Healthcare (PBH)	$4.3B
ICU Medical (ICUI)	$3.9B
Envista Holdings (NVST)	$3.7B
Perrigo (PRGO)	$3.4B
Haemonetics (HAE)	$3.2B
GN Store Nord (GNNDY)	$3.1B
Shandong Weigao Medical Polymer (SHWGF)	$3B
QuidelOrtho (QDEL)	$2.8B
Neogen (NEOG)	$2.3B